Role of microRNAs in hepatocellular carcinoma: a clinical perspective.

MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ (2014) 1.17

The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int (2014) 1.03

MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3'UTR. Acta Pharmacol Sin (2014) 1.02

microRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1-phosphate receptor 1. Exp Ther Med (2014) 1.00

MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1. Oncotarget (2015) 0.99

MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways. PLoS One (2014) 0.90

Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS One (2014) 0.87

The microRNAs as potential biomarkers for predicting the onset of aflatoxin exposure in human beings: a review. Front Microbiol (2014) 0.84

Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma. Gastroenterol Hepatol Bed Bench (2014) 0.82

Cholesterol-conjugated let-7a mimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy. BMC Cancer (2014) 0.80

PIK3C2A mRNA functions as a miR-124 sponge to facilitate CD151 expression and enhance malignancy of hepatocellular carcinoma cells. Oncotarget (2016) 0.76

Metformin-suppressed differentiation of human visceral preadipocytes: Involvement of microRNAs. Int J Mol Med (2016) 0.75

Protective effect of microRNA-138 against cerebral ischemia/reperfusion injury in rats. Exp Ther Med (2016) 0.75

Over-expression of Thrombospondin 4 correlates with loss of miR-142 and contributes to migration and vascular invasion of advanced hepatocellular carcinoma. Oncotarget (2017) 0.75

Involvement of regucalcin as a suppressor protein in human carcinogenesis: insight into the gene therapy. J Cancer Res Clin Oncol (2014) 0.75

MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59

Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29

A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09

Identification of tissue-specific microRNAs from mouse. Curr Biol (2002) 34.55

Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56

MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58

MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20

Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev (2010) 12.60

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab (2006) 12.41

LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10

MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene (2007) 10.79

Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30

Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05

miR-21-mediated tumor growth. Oncogene (2006) 9.90

Human embryonic stem cells express a unique set of microRNAs. Dev Biol (2004) 8.87

Stem cell division is regulated by the microRNA pathway. Nature (2005) 7.79

Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem (2007) 7.46

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95

Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 5.97

OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature (2010) 5.73

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology (2010) 5.44

Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86

The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71

Cancer stem cells: an evolving concept. Nat Rev Cancer (2012) 4.57

Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell (2011) 4.54

Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50

miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell (2009) 4.48

MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology (2009) 4.36

Epidemiology of hepatocellular carcinoma. Clin Liver Dis (2005) 4.29

Metastatic patterns in adenocarcinoma. Cancer (2006) 4.16

miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15

MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene (2008) 4.11

Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92

Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res (2008) 3.67

Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene (2009) 3.51

MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest (2012) 3.46

Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog (2010) 3.44

Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology (2010) 3.37

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res (2013) 3.22

The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res (2008) 3.21

MicroRNAs in human cancer. Adv Exp Med Biol (2013) 3.19

MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem (2009) 3.16

Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14

MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther (2009) 3.05

MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res (2008) 2.97

miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet (2012) 2.89

miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell (2010) 2.87

MicroRNAs: a new class of regulatory genes affecting metabolism. Cell Metab (2006) 2.84

MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int (2012) 2.77

NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A (2011) 2.74

Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology (2010) 2.64

Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One (2011) 2.48

Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist (2009) 2.37

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35

Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer (2008) 2.35

MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28

MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem (2008) 2.28

Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol (2011) 2.18

MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2009) 2.16

Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med (2008) 2.14

miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res (2012) 2.13

miRBase: microRNA sequences and annotation. Curr Protoc Bioinformatics (2010) 2.13

Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn (2010) 2.00

MicroRNAs in human cancer: from research to therapy. J Cell Sci (2007) 2.00

Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A (2010) 1.94

Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) (2011) 1.91

MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology (2013) 1.87

MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84

Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther (2010) 1.81

MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene (2011) 1.81

Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology (2013) 1.79

MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res (2011) 1.79

Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One (2011) 1.78

Apoptosis and the target genes of microRNA-21. Chin J Cancer (2011) 1.74

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res (2010) 1.63

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59

Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol (2008) 1.58

Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57

Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1α in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J Gastroenterol Hepatol (2011) 1.56

The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One (2008) 1.56

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res (2000) 1.55

miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun (2008) 1.53

Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun (2011) 1.52

Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer (2010) 1.51

miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res (2011) 1.51

Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open (2012) 1.50

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res (2012) 1.50

Mechanisms of control of microRNA biogenesis. J Biochem (2010) 1.48

Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog (2009) 1.47

A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26

Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29

MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02

miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51

MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59

An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A (2004) 13.66

E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56

A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24

Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40

Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors. Oncogene (2002) 5.40

Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40

Micro-RNA profiling in kidney and bladder cancers. Urol Oncol (2007) 4.35

MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33

Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35

Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16

Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65

CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57

mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer (2007) 2.40

Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res (2010) 2.30

MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28

In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol (2012) 2.27

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25

MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2009) 2.16

Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A (2010) 2.05

Open letter to Senator Rita Levi-Montalcini. Science (2008) 2.02

Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn (2010) 2.00

MicroRNAs in human cancer: from research to therapy. J Cell Sci (2007) 2.00

MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med (2008) 1.99

MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One (2009) 1.97

Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood (2005) 1.88

MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84

Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res (2006) 1.71

Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood (2009) 1.70

Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol (2008) 1.68

NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood (2002) 1.63

Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther (2007) 1.57

Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol (2010) 1.53

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res (2012) 1.50

Regulation of microRNA expression: the hypoxic component. Cell Cycle (2007) 1.49

Mechanisms causing imprinting defects in familial Beckwith-Wiedemann syndrome with Wilms' tumour. Hum Mol Genet (2006) 1.38

Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol (2007) 1.37

miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol (2012) 1.34

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget (2012) 1.33

BK virus, JC virus and Simian Virus 40 infection in humans, and association with human tumors. Adv Exp Med Biol (2006) 1.32

Downregulation of the mitochondrial calcium uniporter by cancer-related miR-25. Curr Biol (2012) 1.31

Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer (2006) 1.27

Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology (2012) 1.23

Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res (2004) 1.21

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer (2010) 1.18

Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo. Clin Cancer Res (2005) 1.18

Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Mol Cancer (2007) 1.17

Oncogenic transformation by BK virus and association with human tumors. Oncogene (2003) 1.16

MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol (2011) 1.15

Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol (2009) 1.14

Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med (2007) 1.14

Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology (2004) 1.10

miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One (2013) 1.10

Simian virus 40 in humans. Infect Agent Cancer (2007) 1.09

miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Mol Cancer (2013) 1.09

Mutated beta-catenin evades a microRNA-dependent regulatory loop. Proc Natl Acad Sci U S A (2011) 1.08

MicroRNAs dysregulation in human malignant pleural mesothelioma. J Thorac Oncol (2011) 1.06

microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem (2011) 1.06

MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation. Free Radic Biol Med (2008) 0.99

Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood. Mol Diagn (2003) 0.96

Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int (2014) 0.96

The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. Proc Natl Acad Sci U S A (2003) 0.95

Loss of methylation at chromosome 11p15.5 is common in human adult tumors. Oncogene (2002) 0.95

From liver cirrhosis to HCC. Intern Emerg Med (2011) 0.95

MicroRNAs: toward the clinic for breast cancer patients. Semin Oncol (2011) 0.94

CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma. Am J Pathol (2012) 0.93

Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PLoS One (2013) 0.93